Lilly halts trial of experimental Alzheimers drug
The trial ended after participants showed abnormal liver biochemistry, the Indianapolis-based drugmaker said Thursday in a statement.
Health Care Businesses
Articles
Caponi to step down as St. Vincent system CEO
After overseeing 15 years of massive growth via mergers, Vince Caponi will become an executive of St. Vincent Health’s parent organization.
Planned Parenthood affiliates in Indiana, Kentucky to merge
The new not-for-profit organization is expected to be named Planned Parenthood of Indiana and Kentucky—or PPINK—and continue to operate the 28 existing health centers between the two states.
IU Health agrees to sell occupational health clinics
US HealthWorks Medical Group, which specializes in workers’ compensation cases, agreed in May to acquire the eight clinics. The deal is expected to close before the end of June.
Drug sold by Lilly tops Avastin in colon cancer survival study
Patients who got Erbitux together with chemotherapy as a first-line treatment lived about four months longer than those who got Avastin with chemotherapy, according to the 592-person study.
Lilly study: 1 in 5 Alzheimer’s patients misdiagnosed
The study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare to pay for use of its brain imaging agent Amyvid.
Work stops on Greenwood pharmaceutical plant
Greenwood officials three years ago approved $8.4 million of incentives for the Elona Biotechnologies project, including the construction loan.
Canada’s Supreme Court won’t hear Lilly appeal on Zyprexa
Eli Lilly claims recent decisions by Canadian courts invalidating 17 drug patents have made the country an outlier among major developed countries.
Lechleiter’s surgery to repair heart goes as planned
Eli Lilly and Co. CEO John Lechleiter underwent a scheduled surgery Monday for a heart defect, and the repair to the aorta is functioning as intended, the Indianapolis-based drugmaker said.
Study rebuts hospitals’ argument on Medicare, rising costs
Rather than raising prices on private health insurers to make up for inadequate payments from the government, hospitals across the country have been raising prices just because they can, according to a new study.
Lilly stops development on cancer drug after failed study
The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018.
Warner Transitional Services to close, lay off 112
Warner relies on funds from the Indiana Family and Social Administration, but the FSSA recently decided to end that funding after numerous complaints against the company went unresolved.
Indiana firms lose ground on Fortune 500 list
Five of the six Hoosier firms that appear in the 2013 rankings slipped from their positions in last year’s list of the largest U.S. companies.
Lilly CEO to step down temporarily due to surgery
John Lechleiter has been suffering from a dilated aorta, Eli Lilly and Co. said Monday. Current CFO Derica Rice will take his place until later this summer.
Lilly’s sales-force restructuring to affect 1,600-plus
Lilly will eliminate 1,624 positions from its U.S. sales force in July, according to a notice the company made to state officials. But some of those workers may be rehired by the firm.
Lilly taking hard look at Pfizer’s new Viagra strategy
Major drugmakers, including Indianapolis-based Eli Lilly and Co., are closely watching Pfizer Inc.’s plan to sell Viagra directly to consumers. The bold move blows up the drug industry’s distribution model.
Nora pharmacy recalls compounded drugs
A pharmacy that makes specialty medications is recalling nearly 100 compounded drugs after federal regulators found potential safety problems during an inspection.
Lilly on the rise as investors run back to pharma stocks
Investors are gaining confidence in the ability of major drugmakers, including Eli Lilly and Co., to improve their pipelines of new products. The big pharma firms begin to report first-quarter earnings this week.
Lilly’s $30.6M tax abatement request clears hurdle
The pharmaceutical firm has $400 million in projects in the works for its facilities south of downtown. City officials have advanced its request for tax breaks to a public hearing and final consideration May 1.
Lilly seeks $30.6M in tax breaks on downtown projects
Indianapolis development officials on Wednesday will weigh the 10-year requests from the pharmaceuticals giant related to a new manufacturing plant and improvements to existing operations downtown.